Investigating Sexual Health After Breast Cancer by Longitudinal Assessment of Patient-Reported Outcomes
Source : https://pubmed.ncbi.nlm.nih.gov/38350335/
Sexual concerns seem frequent, persistent, and insufficiently addressed. Pretreatment concerns, endocrine therapy, and emotional distress are commonly associated factors. A proactive evaluation of sexual health across the care continuum is...
Sexual concerns were frequent, persistent, and insufficiently addressed. Pretreatment concerns, endocrine therapy, and emotional distress were commonly associated factors.
Chemotherapy-Induced Cognitive Impairment in Breast Cancer Survivors: a Systematic Review of Studies From 2000 to 2021
Source : https://pubmed.ncbi.nlm.nih.gov/38351543/
Chemotherapy, affecting cortical and subcortical brain structures, causes a set of cognitive impairments that can lead to impairments in social responsibility acceptance, daily functioning, and quality of life of women....
The evidence does not establish chemotherapy as the sole or primary cause of cognitive deficits, but it does point to a complex interplay of factors, including age, type of chemotherapy, and individual patient characteristics.
Optimising First-Line Subtyping-Based Therapy in Triple-Negative Breast Cancer (FUTURE-SUPER): a Multi-Cohort, Randomised, Phase 2 Trial
Source : https://pubmed.ncbi.nlm.nih.gov/38211606/
For the Chinese translation of the abstract see Supplementary Materials section.
Median PFS was significantly longer in the pooled subtyping-based group than in the control group, highlighting the potential clinical benefits of using molecular subtype-based treatment optimization.
Breast Cancer Disparity and Outcomes in Underserved Women
Source : https://pubmed.ncbi.nlm.nih.gov/38127658/
Women in the United States who continue to face obstacles accessing health care are frequently termed an underserved population . Safety-net health care systems play a crucial role in mitigating...
Mortality rates of Black women were ≤2.6 times higher than those of non-Hispanic White women aged ≤50 years, whereas they were ≤1.2 times higher in Black women versus non-Hispanic White women aged >70 years.
Clinical Considerations of CDK4/6 Inhibitors in HER2 Positive Breast Cancer
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10824891/
Deregulation of cell cycles can result in a variety of cancers, including breast cancer (BC). In fact, abnormal regulation of cell cycle pathways is often observed in breast cancer, leading...
Combination therapy with CDK4/6 inhibition and anti-HER2 targeting can overcome anti-HER2 resistance, synergistically inhibiting cell proliferation, controlling tumor growth in vivo, and delaying tumor recurrence.